Clinical trials · New York, NY
Neoplasms clinical trials in New York
We’re tracking 194 recruiting neoplasms studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07082920RecruitingPhase 1
Combination treatment for advanced prostate cancer
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
New York, New YorkAges 18 years+ - NCT06486454Recruiting
Liver tumor treatment with sound waves
This trial tests a new device that uses sound waves to destroy liver tumors without cutting or needles. It may be an option if you have a liver tumor that can be partly or fully targeted by this technique.
New York, New YorkAges 22 years+ - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT07319871RecruitingPhase 1
Study of two drugs for prostate cancer
This trial tests a new combination of two drugs, pasritamig and JNJ-86974680, for men with a certain type of advanced prostate cancer that has spread to bone or lymph nodes but not to organs like the lungs or liver. It aims to see if this combination is safe and effective.
New York, New YorkAges 18 years+ - NCT07222800RecruitingPhase 3
Testing a new drug plus chemo for stage 4 colorectal cancer
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
New York, New YorkAges 18 years+ - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
New York, New YorkAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
New York, New YorkAges 18 years+ - NCT06445972RecruitingPhase 1/Phase 2
Testing combination therapies for advanced stomach or esophageal cancer
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
New York, New YorkAges 18 years+ - NCT07218926RecruitingPhase 3
New drug vs sunitinib for GIST after imatinib
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
New York, New YorkAges 18 years+ - NCT00288119Recruiting
Study genes in Barrett’s esophagus and esophageal cancer
This study looks at genetic (inherited) factors that may be linked to Barrett’s esophagus and esophageal cancer. It may help researchers understand why these conditions happen in some families and others do not.
New York, New YorkAges 18 years+ - NCT07218380RecruitingPhase 3
Study of Vepugratinib for advanced bladder or urinary tract cancer
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
New York, New YorkAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
New York, New YorkAges 18 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
New York, New YorkAges 18 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT03435796RecruitingPhase 2/Phase 3
Follow-up for people treated with gene-modified T cells
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
New York, New YorkAges Any age - NCT07630974RecruitingPhase 1/Phase 2
New Cancer Drug for Children With Hard-to-Treat Solid Tumors
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
New York, New YorkAges 1 month–17 years - NCT03442465Recruiting
Study of healing and function after bone reconstruction surgery
This study looks at how well people heal and how well they can move and use the repaired bone after reconstructive surgery for bone tumors. It may help doctors understand what recovery looks like and what could improve function over time.
New York, New YorkAges 4 years+ - NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
New York, New YorkAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
New York, New YorkAges Any age - NCT02474160Recruiting
Banking cancer tissue and blood for future research
This study collects and stores leftover or newly taken samples of tissue and blood from people with cancer. The goal is to build a research library that can help investigators study cancer and develop better tests or treatments.
New York, New YorkAges 2 months+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
New York, New YorkAges 18 years+ - NCT04575935RecruitingPhase 3
Minimally invasive surgery after chemotherapy for advanced ovarian cancer
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
New York, New YorkAges 18 years+ - NCT06469944RecruitingPhase 1/Phase 2
Study of drug combinations for stomach or esophagus cancer
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
New York, New YorkAges 18 years+ - NCT05882058RecruitingPhase 2
Dose test of a DLL3 cancer drug for neuroendocrine tumors
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
New York, New YorkAges 18 years+
Hear when a new Neoplasms trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Neoplasms trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting neoplasms studies listed above.
- Columbia University Irving Medical Center · 10 studies
- Memorial Sloan Kettering Cancer Center · 6 studies
- NYU Langone Health · 4 studies
- NYU Langone Hospital - Long Island · 4 studies
- Montefiore Medical Center · 3 studies
- New York Cancer and Blood Specialists (North Shore Hematology Oncology Associates P.C.) · 3 studies
- Rutgers Cancer Institute of New Jersey · 3 studies
- Weill Cornell Medicine · 3 studies
What taking part in a neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting neoplasms studies in New York.
Common questions
- Are there neoplasms clinical trials near New York?
- Yes. We're currently tracking 194 recruiting neoplasms studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neoplasms study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neoplasms studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.